IL241042B - Methods for the synthesis of a difluorolactam analog - Google Patents
Methods for the synthesis of a difluorolactam analogInfo
- Publication number
- IL241042B IL241042B IL241042A IL24104215A IL241042B IL 241042 B IL241042 B IL 241042B IL 241042 A IL241042 A IL 241042A IL 24104215 A IL24104215 A IL 24104215A IL 241042 B IL241042 B IL 241042B
- Authority
- IL
- Israel
- Prior art keywords
- difluorolactam
- synthesizing
- analog
- methods
- difluorolactam analog
- Prior art date
Links
- 230000002194 synthesizing effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B39/00—Halogenation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyrrole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799334P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/028933 WO2014144500A2 (en) | 2013-03-15 | 2014-03-14 | Methods of synthesizing a difluorolactam analog |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL241042A0 IL241042A0 (en) | 2015-11-30 |
| IL241042B true IL241042B (en) | 2021-10-31 |
Family
ID=50693998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL241042A IL241042B (en) | 2013-03-15 | 2015-09-02 | Methods for the synthesis of a difluorolactam analog |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9914725B2 (enExample) |
| EP (1) | EP2970234B1 (enExample) |
| JP (1) | JP6368351B2 (enExample) |
| AU (1) | AU2014229065B2 (enExample) |
| CA (1) | CA2903314C (enExample) |
| IL (1) | IL241042B (enExample) |
| WO (1) | WO2014144500A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3176162B1 (en) * | 2012-07-19 | 2020-05-27 | Cayman Chemical Company, Inc. | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
| HU231033B1 (hu) * | 2016-03-22 | 2019-12-30 | CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. | Eljárás 3-as kötést tartalmazó optikailag aktív karbonsavak, karbonsav sók és karbonsav származékok előállítására |
| CN106699604B (zh) * | 2017-01-09 | 2019-01-01 | 四川同晟生物医药有限公司 | 一种沙库比曲及其中间体的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009023193A1 (en) * | 2007-08-15 | 2009-02-19 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3975399A (en) | 1974-08-06 | 1976-08-17 | E. I. Du Pont De Nemours And Company | 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones |
| DE2517771A1 (de) | 1975-04-18 | 1976-10-28 | Schering Ag | Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung |
| DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| CA1085859A (en) | 1975-06-27 | 1980-09-16 | Wilhelm Bartmann | Pyrrolidones and process for their manufacture |
| DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
| US4177346A (en) | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
| US4320136A (en) | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
| US4311644A (en) * | 1981-01-30 | 1982-01-19 | E. R. Squibb & Sons, Inc. | Method for preparing 10,10-difluoro prostacyclin intermediates and new compounds produced thereby |
| US4456613A (en) | 1982-12-27 | 1984-06-26 | E. I. Du Pont De Nemours And Company | 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof |
| IL155368A0 (en) | 2000-11-27 | 2003-11-23 | Pfizer Prod Inc | Ep4 receptor selective agonists in the treatment of osteoporosis |
| AU2002226035A1 (en) * | 2000-12-07 | 2002-06-18 | Michael P Doyle | Lewis acid catalysis using chiral metal complexes |
| AU2002328855B2 (en) | 2001-07-16 | 2005-11-24 | F. Hoffmann-La Roche Ag | Prostaglandin Analogues As EP4 Receptor Agonists |
| JP4211605B2 (ja) | 2001-07-16 | 2009-01-21 | 小野薬品工業株式会社 | プロスタノイドアゴニストとしての２ピロリドン誘導体 |
| US7608637B2 (en) * | 2001-07-23 | 2009-10-27 | Ono Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient |
| JP2005514378A (ja) | 2001-12-03 | 2005-05-19 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症の治療方法 |
| DE60307607T2 (de) | 2002-03-18 | 2007-08-09 | Pfizer Products Inc., Groton | Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten |
| WO2003103772A1 (en) | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma |
| CA2483555A1 (en) | 2002-06-10 | 2003-12-18 | Applied Research Systems Ars Holding N.V. | Gamma lactams as prostaglandin agonists and use thereof |
| WO2004037786A2 (en) | 2002-10-25 | 2004-05-06 | Merck Frosst Canada & Co. | 2-pyrrolidones as ep4 receptor agonists |
| ATE394372T1 (de) | 2003-03-03 | 2008-05-15 | Serono Lab | G-lactamderivate als prostaglandinagonisten |
| BRPI0820410A2 (pt) | 2007-10-23 | 2015-05-19 | Allergan Inc | Lactans substituídos terapêuticos |
| WO2011003058A1 (en) | 2009-07-03 | 2011-01-06 | Concert Pharmaceuticals, Inc. | Prostacyclin derivatives |
| JP5847830B2 (ja) | 2010-11-10 | 2016-01-27 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | オレキシン受容体拮抗薬として有用なラクタム誘導体 |
| US9181279B2 (en) * | 2011-07-04 | 2015-11-10 | Rottapharm Biotech S.R.L. | Cyclic amine derivatives as EP4 receptor antagonists |
| EP3176162B1 (en) | 2012-07-19 | 2020-05-27 | Cayman Chemical Company, Inc. | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated disease and conditions |
-
2014
- 2014-03-14 US US14/775,591 patent/US9914725B2/en not_active Expired - Fee Related
- 2014-03-14 JP JP2016502940A patent/JP6368351B2/ja active Active
- 2014-03-14 CA CA2903314A patent/CA2903314C/en active Active
- 2014-03-14 AU AU2014229065A patent/AU2014229065B2/en not_active Ceased
- 2014-03-14 WO PCT/US2014/028933 patent/WO2014144500A2/en not_active Ceased
- 2014-03-14 EP EP14723569.1A patent/EP2970234B1/en active Active
-
2015
- 2015-09-02 IL IL241042A patent/IL241042B/en unknown
-
2018
- 2018-01-30 US US15/883,724 patent/US20180170918A1/en not_active Abandoned
-
2019
- 2019-03-12 US US16/299,916 patent/US11345690B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009023193A1 (en) * | 2007-08-15 | 2009-02-19 | Cytokinetics, Incorporated | Certain chemical entities, compositions, and methods |
Non-Patent Citations (2)
| Title |
|---|
| CID 66622708, DATABASE PUBCHEM COMPOUND, NCBI, 30 November 2012 (2012-11-30) * |
| MARTINEZ-MONTERO, SAUL,, SYNTHESIS, EVALUATION OF ANTI-HIV-1 AND ANTI-HCV ACTIVITY OF NOVEL 2?, 3?-DIDEOXY-2?, 2?-DIFLUORO-4?-AZANUCLEOSIDES., 1 December 2012 (2012-12-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20180170918A1 (en) | 2018-06-21 |
| US9914725B2 (en) | 2018-03-13 |
| JP6368351B2 (ja) | 2018-08-01 |
| JP2016519669A (ja) | 2016-07-07 |
| US11345690B2 (en) | 2022-05-31 |
| EP2970234A2 (en) | 2016-01-20 |
| US20160060253A1 (en) | 2016-03-03 |
| WO2014144500A2 (en) | 2014-09-18 |
| CA2903314A1 (en) | 2014-09-18 |
| IL241042A0 (en) | 2015-11-30 |
| WO2014144500A3 (en) | 2015-05-28 |
| AU2014229065B2 (en) | 2017-03-09 |
| EP2970234B1 (en) | 2018-07-18 |
| US20190202816A1 (en) | 2019-07-04 |
| CA2903314C (en) | 2023-02-14 |
| US20220127252A9 (en) | 2022-04-28 |
| AU2014229065A1 (en) | 2015-09-17 |
| HK1215022A1 (en) | 2016-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201421334D0 (en) | Synthesis of aeizeolite | |
| IL239172A0 (en) | Methods for the synthesis of a prostacyclin analog | |
| GB2511914B (en) | Object production | |
| TWD174480S (zh) | 耳機之部分 | |
| GB201401248D0 (en) | Method of manufacture | |
| PL3155922T3 (pl) | Ornament | |
| TWD174479S (zh) | 耳機之部分 | |
| IL240742A0 (en) | Methods for generating libraries for directed evolution | |
| GB201414400D0 (en) | Object production | |
| GB201305231D0 (en) | Method of Manufacture | |
| IL239697A (en) | Process for making fluorolactone sequelae | |
| IL241042A0 (en) | Methods for the synthesis of a difluorolactam analog | |
| ZA201601775B (en) | Method for the synthesis of irinotecan | |
| GB2528413B (en) | Inhibition of IL-2 production | |
| IL241475A0 (en) | method for synthesis | |
| GB201320732D0 (en) | Methods of chemical synthesis | |
| TWM475821U (en) | Structure of mosquito-catch | |
| SG10201701021XA (en) | Method of synthesis | |
| GB201322922D0 (en) | Synthesis of Polyoxometalates | |
| AU5220P (en) | Jewel of DesertTopaz Delosperma cooperi | |
| GB201310302D0 (en) | Sequencer | |
| GB201322704D0 (en) | Synthesis | |
| PL3071575T3 (pl) | Wytwarzanie normorfinanów | |
| GB201311291D0 (en) | Method of manufacture | |
| GB201301262D0 (en) | Method of manufacture |